​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences stock forecast is as follows: an average price target of $156.14 (represents a 15.30% upside from NBIX’s last price of $135.42) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.

NBIX Price Target

The average price target for Neurocrine Biosciences (NBIX) is $156.14 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $192.00 to $121.00. This represents a potential 15.30% upside from NBIX's last price of $135.42.

NBIX Analyst Ratings

Buy

According to 19 Wall Street analysts, Neurocrine Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for NBIX stock is 0 'Strong Buy' (0.00%), 14 'Buy' (73.68%), 4 'Hold' (21.05%), 1 'Sell' (5.26%), and 0 'Strong Sell' (0.00%).

Neurocrine Biosciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Evan David SeigermanBMO Capital$121.00$120.270.61%-10.65%
Oct 22, 2024Jay OlsonOppenheimer$192.00$116.5764.71%41.78%
Oct 10, 2024Danielle BrillRaymond James$155.00$111.6238.86%14.46%
Sep 13, 2024Evan David SeigermanBMO Capital$128.00$122.294.67%-5.48%
Sep 09, 2024Carter GouldBarclays$160.00$120.1733.14%18.15%
Aug 29, 2024Brian AbrahamsRBC Capital$136.00$123.769.89%0.43%
Aug 29, 2024David AmsellemPiper Sandler$159.00$128.4323.80%17.41%
Jul 12, 2024Jeffrey HungMorgan Stanley$170.00$146.5016.04%25.54%
Jun 06, 2024Brian AbrahamsRBC Capital$141.00$133.695.47%4.12%
May 28, 2024Ashwani VermaUBS$193.00$139.4038.45%42.52%
May 13, 2024Cory KasimovEvercore ISI$175.00$136.1528.53%29.23%
May 02, 2024Sumant KulkarniCanaccord Genuity$164.00$143.0314.66%21.10%
May 02, 2024Andrew FeinH.C. Wainwright$160.00$143.0311.86%18.15%
Apr 23, 2024Mohit BansalWells Fargo$170.00$139.3422.00%25.54%
Mar 12, 2024Jay OlsonOppenheimer$200.00$137.7445.20%47.69%
Feb 03, 2023Morgan Stanley$130.00$108.0020.37%-4.00%
Nov 02, 2022David AmsellemPiper Sandler$103.00$119.36-13.71%-23.94%
Nov 02, 2022Marc GoodmanSVB Securities$115.00$119.36-3.65%-15.08%
Nov 02, 2022Brian SkorneyRobert W. Baird$150.00$119.3625.67%10.77%
Nov 02, 2022Andrew FeinH.C. Wainwright$140.00$119.3617.29%3.38%
Feb 14, 2022Andrew FeinH.C. Wainwright$140.00$86.5261.81%3.38%
Feb 11, 2022Brian SkorneyRobert W. Baird$117.00$85.5336.79%-13.60%
Feb 11, 2022Danielle BrillRaymond James$125.00$85.5346.15%-7.69%
Feb 11, 2022Paul MatteisStifel Nicolaus$136.00$85.5359.01%0.43%
Feb 11, 2022Marc GoodmanLeerink Partners$100.00$85.5316.92%-26.16%
Jan 26, 2022Tazeen AhmadBank of America Securities$127.00$75.5168.19%-6.22%
Jan 20, 2022Carter GouldBarclays$100.00$72.8037.36%-26.16%
Dec 08, 2021Neena Bitritto-GargCitigroup$129.00$84.2653.10%-4.74%
Nov 02, 2021Joshua SchimmerEvercore ISI$130.00$95.5836.01%-4.00%
Nov 02, 2021Charles DuncanCantor Fitzgerald$123.00$95.5828.69%-9.17%
Aug 06, 2021Sumant KulkarniCanaccord Genuity$108.00$89.5720.58%-20.25%
Aug 04, 2021Laura ChicoWedbush$112.00$93.2020.17%-17.29%

The latest Neurocrine Biosciences stock forecast, released on Oct 31, 2024 by Evan David Seigerman from BMO Capital, set a price target of $121.00, which represents a 0.61% increase from the stock price at the time of the forecast ($120.27), and a -10.65% decrease from NBIX last price ($135.42).

Neurocrine Biosciences Price Target by Period

1M3M12M
# Anlaysts-315
Avg Price Target-$156.00$161.60
Last Closing Price$135.42$135.42$135.42
Upside/Downside-100.00%15.20%19.33%

In the current month, the average price target of Neurocrine Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Neurocrine Biosciences's last price of $135.42. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2024RBC CapitalMarket PerformMarket PerformHold
Oct 29, 2024Raymond JamesUnderperformUnderperformHold
Oct 22, 2024OppenheimerOutperformOutperformHold
Oct 14, 2024Piper SandlerOverweightOverweightHold
Oct 04, 2024Piper SandlerUnderperformUnderperformHold
Oct 04, 2024RBC CapitalSector PerformSector PerformHold
Sep 13, 2024William BlairOutperformOutperformHold
Sep 13, 2024BMO CapitalMarket PerformMarket PerformHold
Sep 09, 2024RBC CapitalMarket PerformMarket PerformHold
Sep 09, 2024Piper SandlerUnderperformUnderperformHold
Sep 09, 2024BarclaysOverweightOverweightHold
Aug 29, 2024RBC CapitalSector PerformSector PerformHold
Aug 29, 2024Piper SandlerOverweightUpgrade
Aug 28, 2024Cowen & Co.BuyBuyHold
Aug 19, 2024WedbushSector PerformSector PerformHold
Aug 19, 2024JefferiesBuyBuyHold
Aug 02, 2024OppenheimerOutperformOutperformHold
Aug 02, 2024H.C. WainwrightBuyBuyHold
Aug 01, 2024UBSUnderperformUnderperformHold
Aug 01, 2024WedbushBuyBuyHold
Jul 12, 2024Morgan StanleyOverweightOverweightHold
Jul 10, 2024Wells FargoMarket PerformMarket PerformHold
Jun 05, 2024Wells FargoOverweightOverweightHold
May 28, 2024Wells FargoMarket PerformMarket PerformHold
May 28, 2024UBSBuyBuyHold
May 22, 2024RBC CapitalSector PerformSector PerformHold
May 22, 2024Evercore ISIOutperformOutperformHold
May 02, 2024GuggenheimBuyBuyHold
May 02, 2024H.C. WainwrightBuyBuyHold
Apr 23, 2024Wells FargoBuyOverweightUpgrade
Feb 08, 2024Goldman SachsUnderperformUnderperformHold
Feb 08, 2024Wells FargoBuyBuyHold
Jan 23, 2024Wells FargoMarket PerformMarket PerformHold
Jan 23, 2024RBC CapitalUnderperformUnderperformHold
Nov 01, 2023Raymond JamesOutperformOutperformHold
Sep 13, 2023BMO CapitalMarket PerformMarket PerformHold
Jul 24, 2023Leerink PartnersOutperformUpgrade
Jul 24, 2023MoffettNathansonOutperformUpgrade
Jul 06, 2023BMO CapitalMarket PerformPerformUpgrade
Jul 06, 2023BMO CapitalMarket PerformUpgrade
May 04, 2023GuggenheimBuyUpgrade
Mar 30, 2023Canaccord GenuityBuyUpgrade
Mar 03, 2023Evercore ISIOutperformUpgrade
Feb 03, 2023OppenheimerOutperformInitialise
Feb 03, 2023Morgan StanleyOverweightUpgrade
Dec 07, 2022William BlairOutperformOutperformHold
Sep 26, 2022Wells FargoEqual-WeightInitialise
Sep 26, 2022Credit SuisseOutperformInitialise
Sep 26, 2022CitigroupSellInitialise

Neurocrine Biosciences's last stock rating was published by RBC Capital on Oct 29, 2024. The company gave NBIX a "Market Perform" rating, the same as its previous rate.

Neurocrine Biosciences Financial Forecast

Neurocrine Biosciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$498.80M$452.70M$420.40M$412.00M$387.90M$378.20M$310.60M$312.00M$296.00M$288.90M$236.60M$247.90M$258.50M$302.40M$237.10M$244.01M$222.09M
Avg Forecast$899.46M$868.51M$836.75M$798.88M$742.23M$705.85M$672.04M$624.95M$630.01M$600.64M$545.98M$512.40M$518.52M$479.09M$447.34M$410.66M$408.87M$377.00M$342.33M$304.07M$317.49M$297.83M$273.19M$250.67M$260.45M$282.70M$261.31M$226.53M$231.54M$211.97M
High Forecast$932.65M$900.55M$867.62M$828.35M$769.62M$731.89M$696.83M$650.08M$636.36M$601.79M$545.98M$512.40M$522.66M$506.87M$463.84M$425.81M$423.95M$377.00M$342.33M$304.07M$317.49M$297.83M$273.19M$250.67M$260.45M$282.70M$261.31M$226.53M$231.54M$211.97M
Low Forecast$875.89M$845.75M$814.82M$777.94M$722.78M$687.35M$654.42M$608.16M$625.25M$599.48M$545.98M$512.40M$513.94M$279.75M$435.61M$399.90M$398.15M$377.00M$342.33M$304.07M$317.49M$297.83M$273.19M$250.67M$260.45M$282.70M$261.31M$226.53M$231.54M$211.97M
# Analysts33454527168661223131219181716111111221159644
Surprise %-------------1.04%1.01%1.02%1.01%1.03%1.10%1.02%0.98%0.99%1.06%0.94%0.95%0.91%1.16%1.05%1.05%1.05%

Neurocrine Biosciences's average Quarter revenue forecast for Dec 23 based on 12 analysts is $518.52M, with a low forecast of $513.94M, and a high forecast of $522.66M. NBIX's average Quarter revenue forecast represents a 3.95% increase compared to the company's last Quarter revenue of $498.80M (Sep 23).

Neurocrine Biosciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168661223131219181716111111221159644
EBITDA-------------$141.20M$73.60M$29.70M$103.40M$91.80M$58.60M$6.40M$-4.20M$39.90M$66.30M$36.10M$51.70M$-46.40M$93.60M$49.20M$48.86M$68.45M
Avg Forecast$210.34M$203.10M$195.68M$186.82M$173.57M$165.06M$157.16M$146.15M$147.33M$140.46M$127.68M$47.57M$121.26M$112.04M$104.61M$43.24M$-8.86M$88.35M$80.22M$39.31M$74.40M$69.80M$64.02M$48.84M$61.04M$66.25M$61.24M$62.87M$54.26M$49.68M
High Forecast$218.10M$210.60M$202.90M$193.71M$179.98M$171.15M$162.96M$152.02M$148.82M$140.73M$127.68M$57.08M$122.23M$118.53M$108.47M$51.89M$-7.09M$88.35M$80.22M$47.17M$74.40M$69.80M$64.02M$58.61M$61.04M$66.25M$61.24M$75.44M$54.26M$49.68M
Low Forecast$204.83M$197.78M$190.55M$181.92M$169.02M$160.74M$153.04M$142.22M$146.22M$140.19M$127.68M$38.05M$120.19M$65.42M$101.87M$34.59M$-10.63M$88.35M$80.22M$31.45M$74.40M$69.80M$64.02M$39.07M$61.04M$66.25M$61.24M$50.29M$54.26M$49.68M
Surprise %-------------1.26%0.70%0.69%-11.67%1.04%0.73%0.16%-0.06%0.57%1.04%0.74%0.85%-0.70%1.53%0.78%0.90%1.38%

12 analysts predict NBIX's average Quarter EBITDA for Dec 23 to be $121.26M, with a high of $122.23M and a low of $120.19M. This is -14.12% lower than Neurocrine Biosciences's previous annual EBITDA (Sep 23) of $141.20M.

Neurocrine Biosciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168661223131219181716111111221159644
Net Income-------------$83.10M$95.50M$-76.60M$89.00M$68.50M$-16.90M$13.90M$-7.30M$22.50M$42.30M$32.10M$347.90M$-57.60M$79.60M$37.40M$34.00M$53.79M
Avg Forecast$285.47M$264.78M$249.49M$217.75M$203.09M$174.55M$162.33M$148.90M$169.27M$158.19M$117.69M$24.22M$126.41M$108.41M$84.96M$22.02M$-15.40M$84.11M$63.26M$20.02M$70.39M$57.85M$52.15M$43.43M$62.49M$-2.02M$68.70M$47.79M$80.68M$68.98M
High Forecast$299.16M$277.47M$261.45M$228.19M$212.83M$182.92M$170.11M$174.69M$203.12M$159.99M$117.70M$29.06M$161.09M$149.34M$89.04M$26.42M$-12.32M$84.11M$63.26M$24.02M$70.39M$57.85M$52.15M$52.12M$62.49M$-2.02M$68.70M$57.35M$80.68M$68.98M
Low Forecast$275.74M$255.75M$240.99M$210.33M$196.17M$168.60M$156.79M$124.28M$140.70M$156.40M$117.67M$19.38M$46.98M$38.72M$82.07M$17.61M$-18.48M$84.11M$63.26M$16.01M$70.39M$57.85M$52.15M$34.74M$62.49M$-2.02M$68.70M$38.23M$80.68M$68.98M
Surprise %-------------0.77%1.12%-3.48%-5.78%0.81%-0.27%0.69%-0.10%0.39%0.81%0.74%5.57%28.56%1.16%0.78%0.42%0.78%

Neurocrine Biosciences's average Quarter net income forecast for Dec 23 is $126.41M, with a range of $46.98M to $161.09M. NBIX's average Quarter net income forecast represents a 52.12% increase compared to the company's last Quarter net income of $83.10M (Sep 23).

Neurocrine Biosciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168661223131219181716111111221159644
SG&A-------------$204.20M$221.80M$242.70M$182.90M$186.30M$182.80M$200.70M$156.50M$154.60M$143.20M$129.00M$106.50M$112.50M$96.50M$117.80M$101.21M$84.49M
Avg Forecast$423.50M$408.92M$393.97M$376.14M$349.47M$332.33M$316.42M$294.24M$296.63M$282.80M$257.06M$349.70M$244.14M$225.57M$210.62M$317.91M$330.19M$177.50M$161.18M$289.01M$149.49M$140.23M$128.62M$174.53M$122.63M$133.10M$123.04M$150.52M$109.02M$99.80M
High Forecast$439.12M$424.01M$408.50M$390.01M$362.36M$344.60M$328.09M$306.08M$299.62M$283.34M$257.06M$419.64M$246.08M$238.65M$218.39M$381.49M$396.23M$177.50M$161.18M$346.81M$149.49M$140.23M$128.62M$209.44M$122.63M$133.10M$123.04M$180.63M$109.02M$99.80M
Low Forecast$412.40M$398.20M$383.64M$366.28M$340.31M$323.62M$308.12M$286.34M$294.39M$282.25M$257.06M$279.76M$241.98M$131.72M$205.10M$254.33M$264.15M$177.50M$161.18M$231.21M$149.49M$140.23M$128.62M$139.62M$122.63M$133.10M$123.04M$120.42M$109.02M$99.80M
Surprise %-------------0.91%1.05%0.76%0.55%1.05%1.13%0.69%1.05%1.10%1.11%0.74%0.87%0.85%0.78%0.78%0.93%0.85%

Neurocrine Biosciences's average Quarter SG&A projection for Dec 23 is $244.14M, based on 12 Wall Street analysts, with a range of $241.98M to $246.08M. The forecast indicates a 19.56% rise compared to NBIX last annual SG&A of $204.20M (Sep 23).

Neurocrine Biosciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527168661223131219181716111111221159644
EPS-------------$0.85$0.98$-0.79$0.92$0.72$-0.18$0.15$-0.08$0.24$0.45$0.34$3.72$-0.62$0.86$0.40$0.37$0.59
Avg Forecast$2.74$2.54$2.39$2.09$1.95$1.67$1.56$1.43$1.62$1.52$1.13$1.10$1.21$1.04$0.81$0.62$1.12$0.81$0.61$0.35$0.68$0.56$0.50$0.53$0.60$-0.02$0.66$0.52$0.78$0.66
High Forecast$2.87$2.66$2.51$2.19$2.04$1.75$1.63$1.67$1.95$1.53$1.13$1.10$1.54$1.43$0.85$0.65$1.17$0.81$0.61$0.35$0.68$0.56$0.50$0.53$0.60$-0.02$0.66$0.52$0.78$0.66
Low Forecast$2.64$2.45$2.31$2.02$1.88$1.62$1.50$1.19$1.35$1.50$1.13$1.10$0.45$0.37$0.79$0.60$1.08$0.81$0.61$0.35$0.68$0.56$0.50$0.53$0.60$-0.02$0.66$0.52$0.78$0.66
Surprise %-------------0.82%1.20%-1.28%0.82%0.89%-0.30%0.43%-0.11%0.43%0.90%0.64%6.19%31.94%1.30%0.77%0.48%0.89%

According to 12 Wall Street analysts, Neurocrine Biosciences's projected average Quarter EPS for Dec 23 is $1.21, with a low estimate of $0.45 and a high estimate of $1.54. This represents a 42.59% increase compared to NBIX previous annual EPS of $0.85 (Sep 23).

Neurocrine Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
AVDLAvadel Pharmaceuticals$10.73$30.00179.59%Buy
IRWDIronwood Pharmaceuticals$3.53$8.50140.79%Buy
DVAXDynavax$12.90$29.00124.81%Buy
EVOEvotec SE$4.78$8.0067.36%Buy
AMPHAmphastar Pharmaceuticals$40.85$66.0061.57%Buy
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
COLLCollegium Pharmaceutical$30.90$42.3336.99%Buy
ALKSAlkermes$30.75$37.5021.95%Hold
PCRXPacira BioSciences$19.83$23.7519.77%Hold
NBIXNeurocrine Biosciences$136.69$156.1414.23%Buy
PBHPrestige Consumer Healthcare$80.39$89.5011.33%Buy
ITCIIntra-Cellular Therapies$86.96$93.337.33%Buy
SUPNSupernus Pharmaceuticals$36.22$36.00-0.61%Buy

NBIX Forecast FAQ

Is Neurocrine Biosciences a good buy?

Yes, according to 19 Wall Street analysts, Neurocrine Biosciences (NBIX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 73.68% of NBIX's total ratings.

What is NBIX's price target?

Neurocrine Biosciences (NBIX) average price target is $156.14 with a range of $121 to $192, implying a 15.30% from its last price of $135.42. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Neurocrine Biosciences stock go up soon?

According to Wall Street analysts' prediction for NBIX stock, the company can go up by 15.30% (from the last price of $135.42 to the average price target of $156.14), up by 41.78% based on the highest stock price target, and down by -10.65% based on the lowest stock price target.

Can Neurocrine Biosciences stock reach $200?

NBIX's average twelve months analyst stock price target of $156.14 does not support the claim that Neurocrine Biosciences can reach $200 in the near future.

What are Neurocrine Biosciences's analysts' financial forecasts?

Neurocrine Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.75B (high $2.85B, low $2.67B), average EBITDA is $641.94M (high $666.11M, low $625.02M), average net income is $688.86M (high $740.55M, low $645.84M), average SG&A $1.29B (high $1.34B, low $1.26B), and average EPS is $6.6 (high $7.1, low $6.19). NBIX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.4B (high $3.53B, low $3.31B), average EBITDA is $795.94M (high $825.31M, low $775.08M), average net income is $1.02B (high $1.07B, low $982.81M), average SG&A $1.6B (high $1.66B, low $1.56B), and average EPS is $9.76 (high $10.22, low $9.42).

Did the NBIX's actual financial results beat the analysts' financial forecasts?

Based on Neurocrine Biosciences's last annual report (Dec 2023), the company's revenue was $1.89B, beating the average analysts forecast of $1.86B by 1.70%. Apple's EBITDA was $250.9M, missing the average prediction of $381.15M by -34.17%. The company's net income was $249.7M, missing the average estimation of $341.8M by -26.95%. Apple's SG&A was $887.6M, missing the average forecast of $998.23M by -11.08%. Lastly, the company's EPS was $2.56, missing the average prediction of $3.68 by -30.49%. In terms of the last quarterly report (Sep 2023), Neurocrine Biosciences's revenue was $498.8M, beating the average analysts' forecast of $479.09M by 4.12%. The company's EBITDA was $141.2M, beating the average prediction of $112.04M by 26.03%. Neurocrine Biosciences's net income was $83.1M, missing the average estimation of $108.41M by -23.35%. The company's SG&A was $204.2M, missing the average forecast of $225.57M by -9.47%. Lastly, the company's EPS was $0.85, missing the average prediction of $1.04 by -18.22%